Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.62 |
| ▸ | STAT3 | P40763 | 15/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | JUN | P05412 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Shanzhiside Methyl Ester SCHEMBL29965826 | 1.00 | POLB (0.62) | POLBCTDSP1STAT3MAPTMEN1 | |
| Shanzhiside Methyl Ester SCHEMBL28007134 | 1.00 | POLB (0.62) | POLBCTDSP1STAT3MAPTMEN1 | |
| Shanzhiside SCHEMBL306203 | 0.90 | MAPT (0.58) | POLBCTDSP1STAT3MAPTMEN1 | |
| Barlerin SCHEMBL3244727 | 0.87 | POLB (0.56) | POLBCTDSP1STAT3MAPTMEN1 | |
| Barlerin SCHEMBL29425807 | 0.87 | POLB (0.56) | POLBCTDSP1STAT3MAPTMEN1 | |
| Lamalbid SCHEMBL9056954 | 0.85 | POLB (0.66) | POLBCTDSP1STAT3MAPTMEN1 | |
| SCHEMBL29425982 | 0.83 | POLB (0.62) | POLBCTDSP1STAT3MAPTMEN1 | |
| SCHEMBL9056451 | 0.83 | POLB (0.62) | POLBCTDSP1STAT3MAPTMEN1 | |
| Chlorotuberoside SCHEMBL29425799 | 0.83 | POLB (0.62) | POLBCTDSP1STAT3MAPTMEN1 | |
| Phlorigidoside C SCHEMBL29425891 | 0.82 | POLB (0.61) | POLBCTDSP1STAT3MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433595-B2 | Phytoestrogenic compositions for preventing or treating symptoms associated with menopause | NATURAL ENDOTECH CO., LTD. (KR) | 2016-09-06 | — | — | US | disclosed |
| US-9433595-B2 | Phytoestrogenic compositions for preventing or treating symptoms associated with menopause | NATURAL ENDOTECH CO., LTD. (KR) | 2016-09-06 | — | — | US | disclosed |
| US-20110251145-A1 | Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause | NATURAL ENDOTECH CO., LTD. (KR) | 2011-10-13 | — | — | US | disclosed |
| US-20110251145-A1 | Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause | NATURAL ENDOTECH CO., LTD. (KR) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251145-A1 | Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause | ESR1, CYP19A1, GPER1 | POLB 4808/4885CTDSP1 4788/4885STAT3 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.